FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 345:1209-1211 October 18, 2001 Number 16 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

To the Editor: Ridker and colleagues (June 28 issue)¹ demonstrated that the rate of acute coronary events among subjects with a base-line low-density lipoprotein (LDL) cholesterol level below 149.1 mg per deciliter and a C-reactive protein level above 0.16 mg per deciliter was higher among those given placebo than among those treated with lovastatin in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). The authors conclude that C-reactive protein measurements may be useful in targeting statin therapy in patients with relatively low lipid levels. This conclusion is based on a difference of 15 events between the treatment groups and is . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Gervais, M., Pons, S., Nicoletti, A., Cosson, C., Giudicelli, J.-F., Richer, C. (2003). Fluvastatin Prevents Renal Dysfunction and Vascular NO Deficit in Apolipoprotein E-Deficient Mice. Arterioscler. Thromb. Vasc. Bio. 23: 183-189 [Abstract] [Full Text]